Get the Daily Brief
Latest Biotech News
Targeted protein degradation... mapping cross‑species and health consequences
A multidisciplinary review examined the accelerating field of targeted protein degradation and its broader implications for health, ecology and species biology. The authors mapped how modalities...
CAR‑T neurotoxicity: new clinical insights and mitigation strategies
Recent analyses have deepened understanding of neurotoxic events associated with CAR‑T cell therapies and outlined approaches to reduce incidence and severity. Investigators reviewed clinical...
Mid‑stage drug flops... J&J, Biohaven cut losses after clinical failures
Two mid‑stage program failures landed this week: Johnson & Johnson announced it discontinued an eczema candidate acquired for $1.25 billion after it failed to meet efficacy thresholds, while...
Exosomal lncRNAs drive tumor signaling in head, neck and thyroid cancers
A study detailed how exosome‑associated long non‑coding RNAs (lncRNAs) modulate tumor behavior across head, neck and thyroid cancers, identifying specific extracellular RNA signatures that...
CMS unveils Medicare model for GLP‑1s: voluntary pilot to expand access
CMS launched a voluntary Medicare payment model designed to expand coverage for GLP‑1 weight‑loss drugs. The agency framed the program as a pilot to test payment and access pathways for expensive...
FDA greenlights Yartemlea — first approved therapy for fatal post‑transplant complication
The FDA approved Omeros’s complement inhibitor Yartemlea to treat a life‑threatening complication of hematopoietic stem cell transplants. This is the first regulatory approval for the indication,...
Big pharma pipeline wobble: J&J scraps eczema asset; Biohaven drug fails mid‑stage
Johnson & Johnson terminated development of an experimental eczema drug it acquired for $1.25 billion after the asset failed to meet internal efficacy thresholds. Separately, Biohaven reported a...
Study maps CAR‑T neurotoxicity mechanisms — new safety insights
Researchers published new findings that deepen understanding of neurotoxic effects associated with CAR‑T cell therapies. The work dissects mechanistic drivers of neurotoxicity and identifies...
Engineered AAVs sense tumors — a new vector design for precision delivery
A research team unveiled an intelligent design framework for adeno‑associated virus (AAV) vectors that dynamically respond to tumor microenvironment cues to improve targeting and intratumoral...
Nanovaccines retool HCC immunotherapy: preclinical advances
Researchers reported progress in nanovaccine platforms designed to stimulate antitumor immunity against hepatocellular carcinoma (HCC). The study details nanoparticle formulations that deliver...
Targeted protein degradation expands — study flags cross‑species and health impacts
A new analysis examined biological and ecological implications of targeted protein degradation technologies as they move toward therapeutic and research use. The work synthesizes evidence that...
Muse cells reduce neurodegeneration in Parkinson’s models
A translational study reported that muse cells, a class of pluripotent stem cells found in adult tissues, reduced neurodegeneration in Parkinson’s disease models. The investigators documented...
SpatialBench: benchmark exposes agents’ gaps on real spatial biology tasks
SpatialBench, a new benchmark suite, evaluates agent‑based tools on realistic spatial biology analysis workflows and reveals performance gaps between demo scenarios and deployment‑grade tasks. The...
Microbiota signature links breast, colorectal and lung cancers
A multicancer study mapped tumor‑associated microbiota and found overlapping microbial signatures across breast, colorectal and lung cancers. The multidisciplinary team reported conserved taxa and...
CMS rolls out Medicare GLP‑1 model: voluntary expansion of coverage
CMS launched a voluntary payment model to expand Medicare coverage of GLP‑1 weight‑loss drugs, aiming to broaden beneficiary access while testing new payment and utilization rules. The program,...
FDA greenlights Yartemlea – first therapy for fatal stem‑cell transplant complication
The FDA approved Omeros’s complement inhibitor Yartemlea as the first approved therapy for a severe and potentially fatal complication of hematopoietic stem cell transplants. Omeros secured...
J&J shelves eczema asset from $1.25B deal: efficacy fails company bar
Johnson & Johnson said it will discontinue development of the experimental eczema drug JNJ‑5939 (NM26), the asset it acquired for $1.25 billion in 2024, after the program failed to meet internal...
Biohaven’s potassium‑channel candidate fails Phase 2 – second mid‑stage setback
Biohaven reported that its potassium‑channel modulator missed primary endpoints in a Phase 2 trial for major depressive disorder, marking a second mid‑stage failure for the program. The company...
Tumor‑sensing AAVs: design framework aims to sharpen gene delivery
Researchers unveiled an intelligent design framework for adeno‑associated virus (AAV) vectors that respond to tumor microenvironment cues to improve targeting and infiltration into tumors. The...
Nanovaccines for HCC: engineered nanoparticles enter immunotherapy playbook
A new body of work positioned nanovaccine platforms as next‑generation immunotherapies for hepatocellular carcinoma (HCC), detailing nanoparticle formulations that deliver tumor antigens and...